责任编辑：小浪快报 资金流向方面，主力资金净流出433.11万元，特大单买入978.98万元，占比3.02%，卖出595.71万元，占 比1.84%；大单买入7980.49万元，占比24.60%，卖出8796.86万元，占比27.12%。 截至9月30日，联影医疗股东户数3.24万，较上期增加96.28%；人均流通股25444股，较上期减少 29.23%。2025年1月-9月，联影医疗实现营业收入88.59亿元，同比增长27.39%；归母净利润11.20亿元， 同比增长66.91%。 分红方面，联影医疗A股上市后累计派现6.41亿元。 机构持仓方面，截止2025年9月30日，联影医疗十大流通股东中，香港中央结算有限公司位居第七大流 通股东，持股1903.56万股，相比上期减少298.09万股。易方达上证科创板50ETF（588080）位居第八大 流通股东，持股1787.43万股，相比上期减少259.56万股。华夏上证科创板50成份ETF（588000）位居第 九大流通股东，持股1745.84万股，相比上期减少908.62万股。华宝中证医疗ETF（512170）退出十大流 通股东之列。 联影医疗今年以来股价涨2 ...

证券日报网12月24日讯 ，浩瀚深度在接受投资者提问时表示，公司与燧原科技共同打造的智能体服务 一体机的核心应用场景是金融垂类智能客服：主攻银行、保险、券商等，覆盖催收、智能营销、交叉业 务办理等细分场景，以数字员工替代人工客服。未来市场拓展：（1）客户拓展：依托银联覆盖百余家 银行的渠道优势快速渗透，逐步拓展至保险、券商、大厂外呼等领域。（2）技术与生态拓展：联合实 验室持续迭代一体机与模型；算力投入侧重智算交换机、光交换机，保障服务性能与成本优势；同步推 进终端芯片布局，支撑未来ToC智能终端场景。 （编辑 袁冠琳） ...

Group 1 - The core viewpoint of the news is that 联影医疗 (United Imaging Healthcare) has shown significant financial growth in the first three quarters of 2025, with a notable increase in both revenue and net profit compared to the previous year [2] - As of December 24, 2025, the stock price of 联影医疗 closed at 126.35 yuan, reflecting a 0.79% increase, with a trading volume of 34,400 hands and a total transaction amount of 433 million yuan [1] - The company reported a main revenue of 8.859 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 27.39%, and a net profit attributable to shareholders of 1.12 billion yuan, up 66.91% year-on-year [2] Group 2 - In the third quarter of 2025, the company achieved a single-quarter main revenue of 2.843 billion yuan, which is a 75.41% increase year-on-year, and a single-quarter net profit of 122 million yuan, up 143.8% year-on-year [2] - The company has a debt ratio of 30.08% and reported investment income of 606.847 million yuan, with financial expenses of -438.233 million yuan, and a gross profit margin of 47.02% [2] - Over the past 90 days, 25 institutions have rated the stock, with 18 buy ratings and 7 hold ratings, and the average target price set by institutions is 173.12 yuan [2]

证券日报网12月24日讯 ，浩瀚深度在接受投资者提问时表示，公司开发的晨星大模型，前期与中国科 学院联合研发，现在以自主研发为主，同时根据用户需求合理使用部分开源大模型。 （文章来源：证券日报） ...

Core Viewpoint - The stock of United Imaging Healthcare (688271) experienced a decline of 2.37% on December 23, 2025, closing at 125.36 yuan, with significant trading activity and mixed capital flow trends [1]. Group 1: Stock Performance - On December 23, 2025, the stock had a turnover rate of 0.63%, with a trading volume of 51,800 lots and a total transaction value of 655 million yuan [1]. - The net outflow of main funds was 89.13 million yuan, accounting for 13.61% of the total transaction value, while retail investors saw a net inflow of 46.66 million yuan, representing 7.12% of the total [1]. Group 2: Financing and Margin Trading - On the same day, the financing buy amounted to 80.85 million yuan, with financing repayment at 56.38 million yuan, resulting in a net financing increase of 24.47 million yuan [2]. - The margin trading balance stood at 1.099 billion yuan, with no shares sold short and a short balance of 3.03 million yuan [2]. Group 3: Financial Performance - For the first three quarters of 2025, United Imaging Healthcare reported a main revenue of 8.859 billion yuan, a year-on-year increase of 27.39%, and a net profit attributable to shareholders of 1.12 billion yuan, up 66.91% [3]. - In Q3 2025, the company achieved a single-quarter main revenue of 2.843 billion yuan, reflecting a 75.41% year-on-year growth, and a net profit of 122 million yuan, which is a 143.8% increase compared to the previous year [3]. - The company’s gross profit margin was reported at 47.02%, with a debt ratio of 30.08% and investment income of 60.68 million yuan [3]. Group 4: Analyst Ratings - Over the past 90 days, 25 institutions have rated the stock, with 18 buy ratings and 7 hold ratings, while the average target price set by analysts is 173.12 yuan [3].

Core Viewpoint - The medical device sector is experiencing significant growth and investment opportunities, driven by recent regulatory approvals and technological advancements in brain-computer interface (BCI) technology [3][4][5]. Group 1: Market Performance - The medical device index ETF (159898) saw a 1.11% increase, with approximately 20 million yuan net inflow during trading [1]. - Key stocks in the medical device sector, such as Yirui Technology and Furu Medical, reported gains of 4.58% and 6.44% respectively, indicating strong market performance [1]. Group 2: Regulatory Developments - The National Medical Products Administration (NMPA) approved two high-value medical devices, enhancing clinical applications and technological development in the industry [3]. - Recent policies from major cities like Shanghai and Beijing aim to support the medical device industry, focusing on regulatory reforms and innovation [5]. Group 3: Technological Advancements - China has made significant progress in invasive brain-computer interface technology, becoming the second country after the U.S. to enter clinical trials [3]. - The global brain-computer interface market is projected to grow from approximately $2.62 billion in 2024 to $12.4 billion by 2034, with a compound annual growth rate of 17.35% [4]. Group 4: Investment Opportunities - Analysts suggest that the medical device sector may replicate the successful path of innovative pharmaceuticals, with a focus on innovation driving industry growth and global competitiveness [5]. - The medical device index ETF (159898) tracks a diverse range of leading companies in the sector, primarily focusing on A-share medical devices [7].

中泰证券指出，医疗器械行业政策扰动逐步出清，国内需求恢复、出海逻辑兑现，高值耗材、医疗设备率先走出拐点，IVD、低值耗材有望边际改 善。 招商证券也表示，医疗器械板块2026年关注院内需求改善带来的库存优化、出口放量等趋势，设备端招投标数据持续转好，有望推动渠道库存改善。 高值耗材集采持续扩面，进口高市占率赛道有望受益借助集采实现国产放量，品牌出海空间大。IVD集采加速国产头部公司提高市占率。 医疗ETF（512170）及其联接基金（联接A：162412，联接C：012323）被动跟踪中证医疗指数，该指数前十大权重股分别为药明康德、迈瑞医疗、联 影医疗、爱尔眼科、泰格医药、康龙化成、新产业、爱美客、鱼跃医疗、乐普医疗。 12月23日，医疗板块不振，全市场最大医疗ETF（512170）持续水下震荡，盘中再失年线！场内高频溢价，或有资金继续在年线附近吸筹，昨日， 512170单日获超9888万元净申购。 成分股方面，AI医疗概念股卫宁健康跌逾2%居首，龙头股齐跌，联影医疗、爱尔眼科、爱美客等均跌逾1%。 | 分时 多日 1分 5分 15分 30分 ▼ 综合屏 F9 前复权 超级香加 画线 工具 Q (2 > | ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 12月23日，医疗板块不振，全市场最大医疗ETF（512170）持续水下震荡，盘中再失年线！场内高频溢 价，或有资金继续在年线附近吸筹，昨日，512170单日获超9888万元净申购。 成份股方面，AI医疗概念股卫宁健康跌逾2%居首，龙头股齐跌，联影医疗、爱尔眼科、爱美客等均跌 逾1%。 招商证券也表示，医疗器械板块2026年关注院内需求改善带来的库存优化、出口放量等趋势，设备端招 投标数据持续转好，有望推动渠道库存改善。高值耗材集采持续扩面，进口高市占率赛道有望受益借助 集采实现国产放量，品牌出海空间大。IVD集采加速国产头部公司提高市占率。 医疗ETF（512170）及其联接基金（联接A：162412，联接C：012323）被动跟踪中证医疗指数，该指 数前十大权重股分别为药明康德、迈瑞医疗、联影医疗、爱尔眼科、泰格医药、康龙化成、新产业、爱 美客、鱼跃医疗、乐普医疗。 | | | 医药板块怎么投? ETF"全家桶"请查收! | | | | --- | --- | --- | --- | --- | | | 投港股医药 | | 投A股医 ...

Investment Rating - The report maintains a focus on the innovative drug and medical device industry chain, indicating a high level of interest in this sector [1][6]. Core Insights - The innovative drug sector is experiencing high prosperity, with a recommendation to pay attention to pharmaceutical companies that are likely to see a revaluation of their value, such as Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [6][25]. - The report highlights the Biopharma/Biotech sector, which is expected to see performance improvements as innovative pipelines are realized, with companies like Innovent Biologics, BeiGene, and others being of particular interest [6][25]. - Attention is also drawn to CXO and upstream companies benefiting from innovation, including WuXi AppTec and WuXi Biologics [6][25]. - The report emphasizes the potential recovery of leading medical device companies such as United Imaging Healthcare and Lepu Medical [6][25]. Summary by Sections A-Shares Performance - In the third week of December 2025, the A-share pharmaceutical sector performed similarly to the overall market, with the Shanghai Composite Index rising by 0.03% and the SW Pharma and Biotech index falling by 0.1%, ranking 19th among Shenwan primary industries [8][10]. - Sub-sectors that performed relatively well included pharmaceutical commerce (+4.9%), medical equipment (+1.2%), and medical services (+0.5%) [10][25]. - Notable individual stock performances included Anhui Huaren Health Pharmaceutical Co., Ltd. (+55.9%), Luyan Pharma (+36.8%), and ShuYu Civilian (+35.7%) [13][25]. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector underperformed the market, with the Hang Seng Healthcare index down by 1.8% and the Hang Seng Index down by 1.1% [19][25]. - In contrast, the U.S. pharmaceutical sector outperformed the market, with the S&P Healthcare Select Sector rising by 0.6% compared to the S&P 500's 0.1% increase [19][25].

截至2025年12月22日收盘，联影医疗（688271）报收于128.4元，较前一交易日上涨0.83%，最新总市值 为1058.22亿元。该股当日开盘127.79元，最高128.42元，最低126.72元，成交额达3.99亿元，换手率为 0.38%。 近日，联影医疗发布关于召开2025年第一次临时股东会的会议资料，其中包含《关于2026年度日常关联 交易预计的议案》。根据公告，本次会议将审议公司2026年度与关联方之间的日常关联交易计划，涉及 向关联方采购原材料、销售产品、提供劳务、接受服务及商标授权许可等事项，预计2026年度总交易金 额为105,707.65万元。各类别交易的具体金额及占比已在议案中列明。会议将采用现场与网络投票相结 合的方式进行，现场会议定于2025年12月30日举行。 最新公告列表 《联影医疗2025年第一次临时股东会会议资料》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...